创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels' ELISpot Platform: A New Perspective on Cellular Immunity

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-19 14:06
  • Views:

(Summary description)With the continuous development of biotechnology, people's understanding of cellular immunity mechanism is getting deeper and deeper. As a highly sensitive and specific immunoassay technology, the InnoModels Biotechnology ELISpot platform provides researchers and clinicians with a new perspective to explore cellular immune responses in depth.

InnoModels' ELISpot Platform: A New Perspective on Cellular Immunity

(Summary description)With the continuous development of biotechnology, people's understanding of cellular immunity mechanism is getting deeper and deeper. As a highly sensitive and specific immunoassay technology, the InnoModels Biotechnology ELISpot platform provides researchers and clinicians with a new perspective to explore cellular immune responses in depth.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-19 14:06
  • Views:
Information

With the continuous development of biotechnology, people's understanding of cellular immunity mechanism is getting deeper and deeper. As a highly sensitive and specific immunoassay technology, the InnoModels Biotechnology ELISpot platform provides researchers and clinicians with a new perspective to explore cellular immune responses in depth.
1. High sensitivity and specificity
The ELISpot platform employs an enzyme-linked immunospot assay that accurately detects cytokines secreted by individual cells. This high sensitivity allows the platform to accurately capture antigen-specific T cell responses even at very low antigen concentrations. In addition, due to its direct targeting of cell-secreted cytokines, ELISpot technology can accurately reflect the activity of antigen-specific T cells, avoiding the interference of other non-specific responses and ensuring the accuracy of the test results.
2. High-throughput processing capability
InnoModels Bio's ELISpot platform is equipped with high-throughput processing capability, which can test multiple samples at the same time, greatly improving work efficiency. This efficient processing capability allows researchers to process a large number of samples in a short period of time, speeding up research progress and providing powerful support for research in the fields of disease diagnosis, vaccine development and drug screening.

 


3. Intuitive visualization of test results
ELISpot's results are presented in the form of spots on the membrane, which makes the interpretation of the results simple and clear. Researchers can directly observe the number and distribution of spots on the membrane to determine the activity and number of antigen-specific T cells in the sample. This intuitive presentation not only improves the convenience of results interpretation, but also helps researchers better understand the dynamics of the cellular immune response.
4. Accurate quantitative analysis
In addition to the visual presentation of the test results, the ELISpot platform of InnoModels Biotechnology has the ability to perform accurate quantitative analysis. By counting and statistically analyzing the number of spots on the membrane, the number of antigen-specific T-cells can be accurately quantified. This quantitative analysis capability provides researchers with more detailed data support and helps them to better understand the mechanism and regulation of cellular immune response.
Summary
As an advanced immunoassay technology, InnoModels' ELISpot platform features high sensitivity, high specificity, high throughput, intuitive visualization, and precise quantification. These features make the platform have a wide range of application prospects in the fields of immunology research, disease diagnosis, vaccine development and drug screening. With the continuous progress of science and technology and the deepening of people's understanding of cellular immunity mechanisms, the ELISpot platform of InnoModels Biotechnology is expected to play an important role in more fields, and contribute new strength to the development of human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司